Tags

Type your tag names separated by a space and hit enter

Fixed duration MDT in paucibacillary leprosy.
Int J Lepr Other Mycobact Dis. 1991 Jun; 59(2):237-41.IJ

Abstract

The World Health Organization (WHO) has recommended a fixed duration of multidrug therapy (MDT) for paucibacillary leprosy which is currently widely implemented in India. A clinico-pathological study was initiated in 1984 to assess the efficacy of this regimen. The clinical and histological responses of the patients to MDT were assessed at the end of 6 months, when their treatment was stopped, and at 2 1/2 years, when they were released from surveillance, and compared with the responses of a matched patient group to conventional dapsone (DDS) monotherapy during the same period. Of 28 patients who completed the MDT schedule, there was less than 60% improvement in 33% of them when treatment was stopped at the end of 6 months and in 20% of them at the end of 2 1/2 years. Of 26 patients receiving DDS monotherapy, 37% showed less than 60% improvement at the end of 6 months but only 8.8% had less than 60% improvement at 2 1/2 years. It is concluded that MDT for paucibacillary leprosy as recommended by WHO may not have a major advantage over DDS monotherapy, since about 20% of those patients on MDT continue to have evidence of active disease when discharged from surveillance.

Authors+Show Affiliations

Department of Dermatology, Christian Medical College & Hospital, Vellore, South India.No affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

2071980

Citation

Mathai, R, et al. "Fixed Duration MDT in Paucibacillary Leprosy." International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, vol. 59, no. 2, 1991, pp. 237-41.
Mathai R, George S, Jacob M. Fixed duration MDT in paucibacillary leprosy. Int J Lepr Other Mycobact Dis. 1991;59(2):237-41.
Mathai, R., George, S., & Jacob, M. (1991). Fixed duration MDT in paucibacillary leprosy. International Journal of Leprosy and Other Mycobacterial Diseases : Official Organ of the International Leprosy Association, 59(2), 237-41.
Mathai R, George S, Jacob M. Fixed Duration MDT in Paucibacillary Leprosy. Int J Lepr Other Mycobact Dis. 1991;59(2):237-41. PubMed PMID: 2071980.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fixed duration MDT in paucibacillary leprosy. AU - Mathai,R, AU - George,S, AU - Jacob,M, PY - 1991/6/1/pubmed PY - 1991/6/1/medline PY - 1991/6/1/entrez SP - 237 EP - 41 JF - International journal of leprosy and other mycobacterial diseases : official organ of the International Leprosy Association JO - Int J Lepr Other Mycobact Dis VL - 59 IS - 2 N2 - The World Health Organization (WHO) has recommended a fixed duration of multidrug therapy (MDT) for paucibacillary leprosy which is currently widely implemented in India. A clinico-pathological study was initiated in 1984 to assess the efficacy of this regimen. The clinical and histological responses of the patients to MDT were assessed at the end of 6 months, when their treatment was stopped, and at 2 1/2 years, when they were released from surveillance, and compared with the responses of a matched patient group to conventional dapsone (DDS) monotherapy during the same period. Of 28 patients who completed the MDT schedule, there was less than 60% improvement in 33% of them when treatment was stopped at the end of 6 months and in 20% of them at the end of 2 1/2 years. Of 26 patients receiving DDS monotherapy, 37% showed less than 60% improvement at the end of 6 months but only 8.8% had less than 60% improvement at 2 1/2 years. It is concluded that MDT for paucibacillary leprosy as recommended by WHO may not have a major advantage over DDS monotherapy, since about 20% of those patients on MDT continue to have evidence of active disease when discharged from surveillance. SN - 0148-916X UR - https://www.unboundmedicine.com/medline/citation/2071980/Fixed_duration_MDT_in_paucibacillary_leprosy_ L2 - https://medlineplus.gov/mycobacterialinfections.html DB - PRIME DP - Unbound Medicine ER -